|
|
Phase II Randomized Pilot Study of ALVAC-CEA-B7.1 Vaccine and Chemotherapy, With or Without Tetanus Toxoid, Versus Chemotherapy Alone in Patients With Metastatic Colorectal Adenocarcinoma
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Trial Contact Information Registry Information
Alternate Title
Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI, Pharmaceutical / Industry
|
|
|
|
CPMC-14534 CPMC-BB-IND-9911, FCCC-01015, APL-COL13, NCI-G01-2033, NCT00027833
|
|
|
Objectives - Determine the safety of ALVAC-CEA-B7.1 vaccine and chemotherapy, with or without tetanus toxoid, vs chemotherapy alone in patients with metastatic colorectal adenocarcinoma.
- Determine whether tetanus toxoid enhances the immune response in patients treated with the vaccine and chemotherapy.
Entry Criteria Disease Characteristics:
- Histologically confirmed metastatic colorectal adenocarcinoma
- No clinically active CNS metastases
Prior/Concurrent Therapy:
Biologic therapy: - No prior CEA-directed immunotherapy
- No other concurrent immunotherapy
Chemotherapy: - At least 6 months since prior adjuvant chemotherapy
- No prior chemotherapy for metastatic disease
- No other concurrent chemotherapy
Endocrine therapy: - No concurrent daily use of systemic steroids
- No concurrent nonsubstitutional hormonal therapy
Radiotherapy: - No prior radiotherapy to more than 50% of all nodal
groups
- No concurrent radiotherapy except for palliative purposes
involving less than 20% of bone marrow reserve
Surgery: - No prior major organ allograft
- Recovered from prior surgery
Other: - At least 28 days since prior investigational
products
- No other concurrent investigational products
Patient Characteristics:
Age: Performance status: Life expectancy: Hematopoietic: - Lymphocyte count at least 1,000/mm3
- Granulocyte count at least 1,500/mm3
- Platelet count at least 100,000/mm3
- Hemoglobin at least 10 g/dL
Hepatic: - Bilirubin less than 1.5 times upper limit of normal
(ULN)
- AST/ALT less than 3 times ULN (5 times ULN if liver metastases
present)
- Alkaline phosphatase less than 3 times ULN (5 times ULN if
liver metastases present)
- No hepatocellular dysfunction
- No cirrhosis
Renal: - Creatinine less than 2.5 mg/dL
Cardiovascular: - No uncontrolled coronary artery disease
- No symptomatic congestive heart failure
Pulmonary: - No uncontrolled chronic obstructive lung disease
Gastrointestinal: - No unsolved bowel obstruction or subobstruction
- No uncontrolled Crohn's disease
- No ulcerative colitis
- No concurrent chronic diarrhea
Immunologic: - HIV negative
- No immunocompromised patients
- No diagnosis of altered immune function, including:
- Lupus erythematosus
- Sjogren's syndrome
- Scleroderma
- Myasthenia gravis
- Goodpasture's disease
- Addison's disease
- Hashimoto's thyroiditis
- Active Graves' disease
- No known allergy to egg products or neomycin
- No prior adverse reaction to tetanus toxoid-containing
vaccines
Other: - No significant comorbid medical function
- No uncontrolled infection
- No unstable diabetes mellitus
- No uncontrolled thyroid function abnormalities
- No other malignancy within the past 5 years except basal cell
carcinoma or adequately treated carcinoma in situ of the cervix
- No other medical illness or mental status that would preclude
study participation
- No prior severe toxicity to adjuvant chemotherapy
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and
for at least 3 months after study participation
Expected Enrollment A total of 90 patients (30 per treatment arm) will be accrued for this study. Outline This is a randomized, open-label, multicenter study. Patients are
randomized to 1 of 3 treatment arms. - Arm I: Patients receive a priming dose of tetanus toxoid. Beginning 2
weeks later, patients receive tetanus toxoid and ALVAC-CEA-B7.1 vaccine
subcutaneously (SC) once weekly for 3 weeks.
Two weeks after the third vaccine administration, patients receive
tetanus toxoid and ALVAC-CEA-B7.1 vaccine SC on day 1 and irinotecan IV over
90 minutes, leucovorin calcium IV, and fluorouracil IV on days 1, 8, 15, and
22. Treatment repeats every 6 weeks for 4 courses in the absence of disease
progression or unacceptable toxicity.
- Arm II: Patients receive ALVAC-CEA-B7.1 vaccine and chemotherapy as in
arm I.
- Arm III: Patients receive chemotherapy as in arm I. After completion
of chemotherapy, patients with partial or complete response may receive
ALVAC-CEA-B7.1 vaccine SC once weekly on weeks 1-3 and 6.
Trial Contact Information
Trial Lead Organizations Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center | | | Howard Kaufman, MD, Protocol chair | | | |
Registry Information | | Official Title | | Pilot Phase II Study of Safety and Immunogenicity of an ALVAC-CEA/B7.1 Vaccine Administered with Chemotherapy, Alone or in Combination with Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients with Metastatic Colorectal Adenocarcinoma | | Trial Start Date | | 2001-12-31 | | Registered in ClinicalTrials.gov | | NCT00027833 | | Date Submitted to PDQ | | 2001-10-17 | | Information Last Verified | | 2003-09-08 | | NCI Grant/Contract Number | | CA13696 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|